Study of lutetium treatment for meningioma after prior therapy
Part of Brain & nervous system, Cancer clinical trials.
This study tests a radioactive drug, lutetium-177 DOTATATE, against standard care for people whose meningioma has grown despite earlier surgery and radiation. The treatment targets a protein on tumor cells, which may slow or stop growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with a meningioma (grade 1, 2, or 3).
- Your tumor has not responded to at least one surgery and at least one round of radiation.
- You cannot or have chosen not to have more surgery or more radiation.
- You have a tumor that can be seen on an MRI and has grown in the past year.
- A PET scan shows your tumor takes up the imaging agent DOTATATE.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether a radioactive medicine called lutetium Lu 177 dotatate is safe and effective for metastatic prostate cancer that has neuroendocrine features. It also checks whether patients’ scans show the cancer absorbs the drug (a requirement to start treatment).
This Phase 2 study tests Lutathera to treat meningioma that cannot be safely removed with surgery and is still growing after radiation. It uses a special scan to make sure the tumor has the right target, and aims to improve tumor control and safety.
This trial tests a radioactive drug called 177Lu-DOTATATE for people with recurrent meningioma (a type of brain tumor) that has grown after surgery and radiation. The drug targets a protein on the tumor cells and delivers radiation directly to them.
This Phase 1/2 study tests a targeted radioactive medicine (Lu-177-satoreotide) for meningiomas that keep coming back or keep growing. It works only if tumor imaging shows the tumor has the right “target” signal, and it aims to see how well it can control the disease and how safe it is.
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
Hear when a new Intracranial Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.